Przejdź do zawartości
Merck

Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption.

Clinical immunology (Orlando, Fla.) (2014-04-03)
Kenji Kishimoto, Ryoji Kobayashi, Hirozumi Sano, Daisuke Suzuki, Hayato Maruoka, Kazue Yasuda, Natsuko Chida, Masafumi Yamada, Kunihiko Kobayashi
ABSTRAKT

Hereditary folate malabsorption (HFM) is a rare autosomal recessive disorder. Severe folate deficiency in HFM can result in immunodeficiency. We describe a female infant with HFM who acquired severe Pneumocystis pneumonia. The objective of the present study was to elucidate her immunological phenotype and to examine the time course of immune recovery following parenteral folate therapy. The patient demonstrated a combined immunodeficiency with an impaired T cell proliferation response, pan-hypogammaglobulinemia, and an imbalanced pro-inflammatory cytokine profile. She had normal white blood cell count, normal lymphocyte subsets, and normal complement levels. Two novel mutations were identified within the SLC46A1 gene to produce a compound heterozygote. We confirmed full recovery of her immunological and neurophysiological status with parenteral folate replacement. The time course of recovery of her immunological profile varied widely, however. HFM should be recognized as a unique form of immunodeficiency.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Folic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Folic acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Folic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
Sigma-Aldrich
Folic acid, ≥97%
Sigma-Aldrich
Folic acid, meets USP testing specifications